Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

ESMO Open(2022)

引用 7|浏览14
暂无评分
摘要
•Evaluation of the efficacy and safety of a switch maintenance therapy with gatipotuzumab.•Patients with TA-MUC1-positive recurrent ovarian, fallopian tube, or primary high-grade serous peritoneal cancer evaluated.•Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced tumor-associated epitope mucin-1.•Gatipotuzumab was well tolerated, with mild to moderate infusion-related reactions.•Gatipotuzumab switch maintenance therapy does not improve outcome in TA-MUC1-positive ovarian cancer patients.
更多
查看译文
关键词
gatipotuzumab,palliative care,TA-MUC 1,ovarian cancer,ADCC
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要